NewsMV
← News·MarketsMarkets

TG Therapeutics (TGTX) in Focus as Betaville Takeover Alert Drives Acquisition Speculation

TG Therapeutics (TGTX) is in focus after Betaville issued an "uncooked" alert on Aug. 21 suggesting a U.S. biopharma company with a market cap between $20 billion and $40 billion may be interested in acquiring the…

NM
NewsMV Markets Desk
3 min read
23 August 2026Markets desk
Share this dispatch

Key takeaways

  • Betaville issued an "uncooked" alert on Aug. 21 suggesting a U.S. biopharma with a $20 billion to $40 billion market cap may be interested in acquiring TG Therapeutics (TGTX).
  • Betaville named no buyer, and TG Therapeutics has not confirmed any acquisition discussions are underway.
  • BRIUMVI, TG Therapeutics' multiple sclerosis therapy, generated $227.7 million in U.S. Q2 revenue, a 64% year-over-year gain, prompting management to raise the 2026 revenue target to about $950 million.
  • TGTX shares are up roughly 85% year-to-date, with Wall Street at a "Moderate Buy" consensus and a mean price target near $64, implying about 17% additional upside.
  • The confirmed commercial performance and the unconfirmed acquisition thesis are separate risk profiles, leaving the Aug. 21 premium exposed to headline risk absent a formal statement or named acquirer.

TG Therapeutics (TGTX) is in focus after Betaville issued an "uncooked" alert on Aug. 21 suggesting a U.S. biopharma company with a market cap between $20 billion and $40 billion may be interested in acquiring the biotech. Betaville named no buyer, and TG Therapeutics has not confirmed that any discussions are underway. The next confirmable event is a formal statement from either party or the public identification of a named suitor.

The numbers

BRIUMVI, TG Therapeutics' multiple sclerosis therapy, generated U.S. revenue of $227.7 million in Q2, a 64% year-over-year gain. On the strength of that print, management raised the company's 2026 revenue target to approximately $950 million. The company is profitable and actively investing in its commercial buildout and pipeline. TGTX shares are up about 85% year-to-date. Wall Street's consensus sits at "Moderate Buy," with a mean price target near $64, implying roughly 17% additional upside from current levels on the Street's estimate.

The setup

The Betaville label "uncooked" is the qualifier that shapes the risk here. The information has not been fully vetted by the firm. No acquirer has been named, and no formal process has been confirmed. Biotech takeover speculation can lift a stock sharply as investors price in a potential acquisition premium. Those same gains can reverse just as quickly when speculation is denied or fails to produce a transaction.

The fundamental story carries weight on its own terms. BRIUMVI's revenue growth is confirmed in the quarterly print. Management backed it with a guidance raise, and the company's profitability rounds out a commercial profile that explains the strategic interest the Betaville report implies.

Confirmed commercial performance and an unconfirmed acquisition thesis are separate risk profiles. The first is in the numbers. The second has no named counterparty and no filing on record. That gap shapes how durable the premium from Aug. 21 may prove.

What to watch

Watch for any formal statement from TG Therapeutics or a publicly identified acquirer. Absent a definitive agreement or confirmed discussions, the premium priced into TGTX on Aug. 21 remains exposed to the headline risk of unconfirmed speculation.

Related reading

Categorydeals

Filed via finance.yahoo.com

← Back to all dispatchesFront page →
Keep reading

More from the markets desk

MarketsMarkets

London clay-soil drying sends subsidence risk to historic levels

Five consecutive heat waves have dried out the clay-based soil beneath London, pushing the city to historic levels of subsidence risk. Clay contracts as moisture leaves it. Foundations shift when the ground beneath them…

NM
NewsMV Markets Desk
3 min read
MarketsMarkets

PBT monthly dividend set at $0.018701 per share, August 31 ex-date in focus

$PBT is in focus after the trust declared a monthly cash dividend of $0.018701 per share. The ex-dividend date and record date are both set for August 31, and payment follows on September 15. For

NM
NewsMV Markets Desk
3 min read
MarketsMarkets

LFVN sets $0.05 quarterly cash dividend, September 15 payment date confirmed

In focus: LFVN's quarterly cash dividend declaration, $0.05 per share, with the ex-dividend date and the record date both set for September 1, 2026. The payment date is September 15, the next co

NM
NewsMV Markets Desk
3 min read

Frequently asked

Who is reportedly interested in acquiring TG Therapeutics?

Betaville did not name any buyer, describing only a U.S. biopharma company with a market cap between $20 billion and $40 billion as potentially interested; TG Therapeutics has not confirmed any discussions.

What does the Betaville "uncooked" label mean for this report?

"Uncooked" indicates the information has not been fully vetted by the firm, meaning no acquirer has been named and no formal process has been confirmed.

How is BRIUMVI performing financially?

BRIUMVI generated $227.7 million in U.S. revenue in Q2, a 64% year-over-year increase, and helped prompt management to raise the 2026 revenue target to approximately $950 million.

What should investors watch next?

Investors should watch for a formal statement from TG Therapeutics or a publicly identified acquirer, since absent confirmed discussions the Aug. 21 premium remains exposed to headline risk.